

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA



(Please scan this QR Code to view the Prospectus)



# MAHAMAYA LIFESCIENCES LIMITED

Corporate Identification Number: U24233DL2002PLC115261

Our Company was originally incorporated as a private limited Company under the name of "Mahamaya Life Sciences Private Limited" under the provisions of the Companies Act, 1956 and certificate of incorporation was issued by the Assistant Registrar of Companies, NCT of Delhi & Haryana, on May 07, 2002. Further, our Company name was changed from "Mahamaya Life Sciences Private Limited" to "Mahamaya Lifesciences Private Limited" and a fresh certificate of incorporation dated February 15, 2016 was issued by the Registrar of Companies, Delhi. Moreover, a special resolution was passed at the Extra-Ordinary General Meeting of our Company held on October 29, 2024 for conversion of our Company into a public limited Company and the name of our Company was changed from "Mahamaya Lifesciences Private Limited" to "Mahamaya Lifesciences Limited". A fresh certificate of incorporation consequent to change of name was issued by the Registrar of Companies, Delhi on November 19, 2024. The Corporate Identity Number of our Company is U24233DL2002PLC115261.

Registered Office: Unit No: DPT – 033, Ground Floor, Plot No: 79 – 80, DLF Prime Tower, F – Block, Okhla, Phase – 1, New Delhi – 110020, India.

Corporate Office: 369, 370, 370A & 370B, 3rd Floor, Tower B-1, Spaze ITech Park, Sector-49, Sohna Road, Gurugram 122018

Contact Person: Ms. Shilpi Bhardwaj, Company Secretary and Compliance Officer; Tel: +91-1146561474 E-mail: cs@mahamayalifesciences.com Website: https://www.mahamayalifesciences.com/

## PROMOTERS OF OUR COMPANY: Mr. Krishnamurthy Ganesan, Mrs. Lalitha Krishnamurthy and Mr. Prashant Krishnamurthy

## THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LTD (BSE SME)

The company specializes in the manufacturing of pesticide formulations and supply bulk formulations catering to both Indian agrochemical companies, as well as multinational corporations (MNCs). We began our journey by focusing on import and registration of vital pesticide molecules (Technical) that were not produced domestically in India. We imported these molecules after lot of product research and worked on registering them with the Central Insecticides Board and Registration Committee (CIBRC) under the Department of Agriculture, Government of India. After successful registration we marketed these molecules both as technical and as value added end use formulations for both domestic manufacturers and MNCs.

For further details, see chapter titled "Our Business" beginning on page 124 of the Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF UP TO 61,78,000\* EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF MAHAMAYA LIFESCIENCES LIMITED ("MLL" OR THE "COMPANY") FOR CASH AT PRICE OF ₹ 114/- PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF 104/- PER EQUITY SHARE) (THE "OFFER PRICE"), AGGREGATING UP TO ₹ 7,043.80 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF UPTO 56,38,800\* EQUITY SHARES AGGREGATING TO ₹ 6,428.23 LAKHS (THE "FRESH OFFER") AND AN OFFER FOR SALE OF UPTO 5,40,000\* EQUITY SHARES (THE "OFFERED SHARES") OF FACE VALUE OF ₹ 10/- EACH AGGREGATING UP TO ₹ 615.60 LAKHS ("OFFER FOR SALE") COMPRISING OF 3,70,000\* EQUITY SHARES AGGREGATING UP TO ₹ 421.80 LAKHS BY KRISHNAMURTHY GANESAN AND 1,70,000\* EQUITY SHARES AGGREGATING UP TO ₹ 193.80 LAKHS BY LALITHA KRISHNAMURTHY (COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS") OUT OF WHICH 3,09,600 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN OFFER PRICE OF ₹ 114/- PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ 352.94 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE OFFER (THE "MARKET MAKER RESERVATION PORTION"). THE OFFER LESS MARKET MAKER RESERVATION PORTION I.E. NET OFFER OF 58,69,200\* EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN OFFER PRICE OF ₹ 114/- PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ 6,690.89 LAKHS IS HERINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND NET OFFER WILL CONSTITUTE 26.40% AND 25.08% RESPECTIVELY OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ANCHOR INVESTOR OFFER PRICE: RS. 114/- PER EQUITY SHARE.

THE FACE VALUE OF THE EQUITY SHARE IS RS.10/- EACH AND OFFER PRICE IS RS. 114/- PER EQUITY SHARE.

THE OFFER PRICE IS 11.4 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

### BID/OFFER PERIOD

ANCHOR INVESTOR BIDDING DATE WAS: MONDAY, NOVEMBER 10, 2025

BID/OFFER OPENED ON: TUESDAY, NOVEMBER 11, 2025; BID/OFFER CLOSED ON: THURSDAY, NOVEMBER 13, 2025

### RISK TO INVESTORS:

Summary description of key risk factor based on materiality:

- Our top ten customers constituted 71.35%, 76.26%, 83.14% and 71.12% of our sales for the period ended June 30, 2025 and for the financial year ended March 31, 2025, March 31, 2024, March 31, 2023 respectively. Absence of large number of customers, dependence on few customers and creating a customer concentration risk which may have an adverse impact on our business operations and financial performance.
- Our Company has not entered into long-term agreements with our customers for purchasing our products nor for the supply of raw materials with our suppliers. We are subject to uncertainties in demand/supply and there is no assurance that these customers and suppliers will continue to purchase our products or sell raw materials to us or that they will not scale down their orders. This could impact the business and financial performance of our Company.
- Raw materials constitute a significant percentage of our Company's total expenses. Any increase in prices and any decrease in the supply would materially adversely affect our Company's business.
- We are required to obtain and/or renew certain registrations from the CIB&RC for our products manufactured in India. We also register our products in overseas jurisdictions through our International Distribution Partners to enable exports to such countries. Any failure to successfully register our products in India or in the international markets may affect our results of operations and financial condition.
- We have complied with the timely filing requirement for statutory dues but have faced delays in payment due to technical issue.
- We are party to certain litigation and claims. These legal proceedings are pending at different levels of adjudication before various forums and regulatory authorities. Any adverse decision may make us liable to liabilities/penalties and may adversely affect our reputation, business, and financial status.
- Perception of non-compliance due to non-reflection of TDS payment on the TRACES Portal
- We may not be able to avail funding from banks or financial institution for our future working capital requirements. The failure to obtain such financing may adversely affect our ability to grow and our future profitability.
- The Objects of the Offer for which funds are being raised have not been appraised by any bank or financial institution. The deployment of funds is entirely at the discretion of our management and as per the details mentioned in the section titled "Objects of the Offer". Any revision in the estimates may require us to reschedule our expenditure and may have a bearing on our expected revenues and earnings.
- Our Company had negative cash flows, details of which are given below. Sustained negative cash flow could adversely impact our business, financial condition and results of operations.

For further details please refer chapter titled 'Risk Factors' beginning on page no. 31 of the Prospectus.

- The Merchant Banker associated with the Offer has handled 3 Public Issues in the past 3 financial years, out of which nil Issue closed below Issue Price on listing date.
- The average cost of acquisition of Equity Shares by the Individual Promoters is:

Name of Promoters and Selling Shareholders	Number of Equity Shares held	Average Cost of Acquisition per equity share (in Rs.)
Mr. Krishnamurthy Ganesan (Promoter and Selling Shareholder)	54,86,250	0.67
Mrs. Lalitha Krishnamurthy (Promoter and Selling Shareholder)	41,20,875	0.01
Mr. Prashant Krishnamurthy (Promoter)	41,20,875	0.00

As certified by N. Naresh & Co. Chartered Accountant, Statutory Auditor by way of their certificate dated January 09, 2025

• P/E ratio based on the Basic and Diluted EPS, as restated for Financial Year 2024-25 for the Company is 15.00 at cap price

• Weighted Average Return on Net worth for Financial Year 2024-25, 2023-24 and 2022-23 is 23.36%

• The Weighted average cost of acquisition of all Equity Shares transacted in the last eighteen months, one year and three years immediately preceding the date of the Prospectus is set forth below:

Period	Weighted Average Cost of Acquisition (in Rs.)	Cap price of Price Band is 'X' times of the weighted average cost of acquisition	Range of acquisition price: Lowest Price – Highest Price (in Rs.)
Last one year	NA**	NA**	NA**
Last eighteen months	8.24	13.84	0- 201.65
Last three years	8.24	13.84	0- 201.65

\*\*NA = Not Applicable since no transaction in last one year

As certified by M/s N Naresh & Co, Chartered Accountants the statutory auditors of our Company pursuant to their certificate dated November 03, 2025

• Weighted average cost of acquisition at Floor price and Cap Price in the last 18 months:

Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares)	Floor price (i.e. ₹ 108/-)	Cap Price (i.e. ₹ 114/-)
Weighted average cost of acquisition of primary / new issue	75.15	1.44	1.52
Weighted average cost of acquisition for secondary sale/ acquisition	201.65	0.54	0.57

As certified by M/s N Naresh & Co, Chartered Accountants the statutory auditors of our Company pursuant to their certificate dated November 03, 2025

## PROPOSED LISTING: TUESDAY, NOVEMBER 18, 2025

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company and Selling Shareholder, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors wherein (a) one third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than two lots and up to such lots equivalent to not more than ₹ 10 lakhs; (b) two third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than ₹ 10 lakhs; and (c) any unsubscribed portion in either of the sub-categories specified in clauses (a) or (b), may be allocated to Applicants in the other sub-category of Non-Institutional Investors; and not less than 35.00% of the Net Offer shall be available for allocation to Individual Investors, who applies for minimum application size, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page number 316 of this Prospectus

### SUBSCRIPTION DETAILS

The Company received 8 Anchor Investor Application Forms from 8 Anchor Investors (including Nil mutual funds through Nil Mutual Fund schemes) for 2,031,600 Equity Shares. Such 8 Anchor Investors through 7 Anchor Investor Application Forms were allocated 17,52,000 Equity Shares at a price of Rs.114/- per Equity Share under the Anchor Investor Portion, aggregating to Rs. 199,728,000/- The Offer was subscribed to the extent of 1.47 times (including the Anchor Investor Portion) as per the bid books of BSE (the "Bid Files") after removing multiple and duplicate bids & Bid not bank cases. The Details of the Applications received from various categories (before technical rejection) are as under:

Detail of the Applications Received:

Sr. No.	Category	Number of Applications Received*	Number of Equity Shares applied	Number of Equity Shares reserved as per Prospectus	Number of times subscribed	Application Amount (in ₹)
1	Anchor Investors	8	20,31,600	17,52,000	1.16	23,16,02,400
2	Market Maker	1	3,09,600	3,09,600	1.00	3,52,94,400
3	Qualified Institutional Bidders (excluding Anchor Investors)	9	14,01,600	11,76,000	1.19	15,97,82,400
4	Non Institutional Investors -More than 2 Lakhs Upto 10 Lakhs	64	2,67,600	2,94,000	0.91	3,05,06,400
5	Non Institutional Investors -Above 10 Lakhs	82	29,41,200	5,88,000	5.00	33,52,96,800
6	Individual Investors	882	21,16,800	20,59,200	1.03	24,11,49,600
<b>TOTAL</b>		<b>1,046</b>	<b>90,68,400</b>	<b>61,78,800</b>	<b>1.47</b>	<b>1,03,36,32,000</b>

Final Demand

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid Prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	108	69,600	0.63	69,600	0.63
2	109	4,800	0.04	74,400	0.68
3	110	14,400	0.13	88,800	0.81
4	111	4,800	0.04	93,600	0

Please refer to RFP No.SBI/GITC/NWTech/2025-26/1396 dated 18.10.2025 for Procurement of Domain Name System (DNS) Solution of State Bank of India. Corrigendum - 2 dated 17.11.2025 can be accessed under Procurement Requests on Bank's website <https://www.sbi.co.in> or <https://sbi.bank.in> or e-Procurement agency portal <https://etender.sbi/SBI/>

Place: Navi Mumbai Date: 17.11.2025

Sd/- Deputy General Manager (Network Technology Dept.)



TATA

(Contracts Department)

RAHARGORAH, JAMSHEDPUR-831016, Jharkhand

### NOTICE INVITING EXPRESSION OF INTEREST

The Tata Power Company Limited invites expression of interest from eligible vendors for the package Name

S.No.	Tender Description	Ref No
1	Catering & Housekeeping Services in Plant & Guest House at IEL-Kalinganagar plant	IEL/MMD/AD/FY26/200008822
2	Scaffolding Services & Insulation Services for IEL-Kalinganagar plant	IEL/MMD/AD/FY26/2000090131
3	Procurement, Installation & Servicing for the Large Video Screen at IEL-Kalinganagar plant	IEL/MMD/AD/FY26/3500010478
4	Services for Major Overhauling of Mechanical Equipment at IEL-Kalinganagar plant	IEL/MMD/AD/FY26/2000087856
5	Employee Transportation Services & Car Rental Services at IEL-Kalinganagar plant	IEL/MMD/AD/FY26/2000089021

For details of pre-qualification requirements, bid security, purchasing of tender document etc., please visit Tender section of our website ([URL: https://www.tatapower.com/tender](https://www.tatapower.com/tender)). Eligible vendors willing to participate may submit their expression of interest along with the tender fee for issue of bid document latest by 30 Nov 2025.

### SHARP INDIA LIMITED

Registered Office : Ghat No. 686/4, Korgoan Bhima, Taluka Shirur, Dist. Pune - 412216 Phone No.: 02137-670000/01 Email id: [secretarial@sil.sharp-world.com](mailto:secretarial@sil.sharp-world.com)

Website : [www.sharpindialimited.com](http://www.sharpindialimited.com) CIN : L36759MH1985PLC036759

### NOTICE TO SHAREHOLDERS

#### OPENING OF SPECIAL WINDOW FOR RE-LODGE OF TRANSFER REQUESTS OF PHYSICAL SHARES

Further to our public notice published on July 12, 2025 and September 16, 2025, we wish to restate that in terms of SEBI vide Circular no. SEBI/HO/MIRSD/MIRSD PoD/P/CIR/2025/97 dated July 02, 2025, a special window has been opened to consider transfer requests of physical shares which were rejected and returned to the lodger on or before March 31, 2019, can be re-logged after rectifying the errors, for registration of transfer from July 07, 2025 to January 06, 2026 with our Registrar and Share Transfer Agents (RTA), i.e. M/s. MUFG Intime India Pvt. Ltd. Transferred Shares will only be issued in demat mode once all the documents are found in order by RTA. Transfer requests submitted after January 06, 2026, will not be accepted by the Company/RTA. The lodger must have a demat account and provide its Client Master List (CML), along with the transfer documents and share certificate, while lodging the documents for transfer with RTA. You may contact RTA for attending these requests by sending email at [pune@in.mpmms.mufg.com](mailto:pune@in.mpmms.mufg.com) or to company at [secretarial@sil.sharp-world.com](mailto:secretarial@sil.sharp-world.com). This is for your information.

For Sharp India Limited

Sd/- Chandrani Belvalkar

Company Secretary  
Membership No. 24015

Place : Pune

Date : November 15, 2025

Continued from previous page...

#### 6) Allocation to Market Maker (After Technical Rejections):

The Basis of Allotment to Market Maker, who have bid at Offer Price of ₹114.00 per equity shares or above, was finalized in consultation with BSE. The category was subscribed by 1.00000 times i.e. for 3,09,600 shares the total number of shares allotted in this category is 3,09,600 Equity Shares to 1 successful applicant. The category wise details of the Basis of Allotment are as under:

S.No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ration of allottees to applicants	Total No. of shares allocated/allotted
ANCHOR	3,09,600	1	100.00	3,09,600	100.00	3,09,600	1:1	3,09,600
<b>TOTAL</b>	<b>3,09,600</b>	<b>1</b>	<b>100.00</b>	<b>3,09,600</b>	<b>100.00</b>			<b>3,09,600</b>

The Board of Directors of the Company at its meeting held on November 14, 2025 has approved the Basis of Allocation of Equity Shares as approved by the Designated Stock Exchange viz. BSE and has authorized the corporate action for issue of the Equity Shares to various successful applicants. The CAN-cum-allotment advices and/or notices will forward to the email id's and address of the Applicants as registered with the depositories / as filled in the application form on or before November 14, 2025. Further, the instructions to Self Certified Syndicate Banks for unblocking the amount will process on or prior to November 14, 2025. In case the same is not received within ten days, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares admitted for trading on the SME platform of BSE Ltd within three working days from the date of the closure of the issue.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated November 14, 2025 ("Prospectus") filed with Registrar of Companies, Delhi.

#### INVESTORS PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, **KFin Technologies Limited** at [www.kfintech.com](http://www.kfintech.com). All future correspondence in this regard may kindly be addressed to the Registrar to the issue quoting full name of the First/ Sole applicants, serial number of the Bid cum Application Form, PAN, Client ID, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:



**KFin Technologies Limited**  
Address: Selenium Tower B, Plot No-31 & 32, Financial District, Nanakramguda, Serilingampally Hyderabad Rangareddi TG 500032  
Tel No.: +91-40-6712222/18003094001  
Fax No.: +91-40-6716 1563  
E-mail: [compliance.corp@kfintech.com](mailto:compliance.corp@kfintech.com)/[mahamaya.ipo@kfintech.com](mailto:mahamaya.ipo@kfintech.com)  
Investor Grievance Email: [einward.ris@kfintech.com](mailto:einward.ris@kfintech.com)  
Website: [www.kfintech.com](http://www.kfintech.com)  
Contact Person: Mr. M. Murli Krishna

For and on behalf Mahamaya Lifesciences Limited  
Sd/- Krishnamurthy Ganeshan  
Managing Director  
DIN: 00270539

Place: Delhi

Date: November 15, 2025

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF MAHAMAYA LIFESCIENCES LIMITED.

**Disclaimer:** Mahamaya Lifesciences Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares. The Prospectus dated November 14, 2025 has been filed with the Registrar of Companies, Delhi. The Prospectus is available on the website of BSE Limited at [www.bseindia.com](http://www.bseindia.com), on the website of the BRLM at [https://www.onviewadvisors.com/](http://www.onviewadvisors.com) and on the website of the Company at [https://www.mahamayalifesciences.com/](http://www.mahamayalifesciences.com/). Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section entitled "Risk Factors" on page 31 of the Prospectus.

The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. Accordingly, the Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made.

**GREENLAM INDUSTRIES LIMITED**  
Registered & Corporate Office: 203, 2<sup>nd</sup> Floor, West Wing, Worldmark 1, Aerocity, IGI Airport, Heliport District, New Delhi-110037, India  
Phone No.: +91-11-4279-1399, CIN: L21016DL2013PLC386045  
Email: [investor.relations@greenlam.com](mailto:investor.relations@greenlam.com); Website: [www.greenlamindustries.com](http://www.greenlamindustries.com)

#### SPECIAL WINDOW FOR RE-LODGE OF TRANSFER REQUEST OF PHYSICAL SHARES

Pursuant to the Securities and Exchange Board of India ("SEBI") Circular No. SEBI/HO/MIRSD/MIRSD PoD/P/CIR/2025/97 dated 2nd July, 2025, the Company is offering a one-time special window for physical shareholders to re-lodge transfer request. The facility is open from July 07, 2025 to January 06, 2026 and applies to cases where original share transfer requests were submitted before April 01, 2019 but were returned / rejected, or left unattended due to documentation or process deficiencies. Please note that re-lodgment will be processed only in dematerialized form during the period. Eligible shareholders may submit their request along with the requisite documents to the Company's Registrar & Transfer Agent, MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited) e-mail: [delhi@in.rmpms.mufg.com](mailto:delhi@in.rmpms.mufg.com).

The shareholders are also reminded to claim their unclaimed dividends, if not claimed within seven years, both dividend and corresponding shares will be transferred to the Investor Education & Protection Fund Authority (IEPFA) as per regulatory norms.

This Notice may also be accessed on [www.greenlamindustries.com](http://www.greenlamindustries.com), [www.nseindia.com](http://www.nseindia.com) & [www.bseindia.com](http://www.bseindia.com)

For Greenlam Industries Limited  
Sd/-  
Prakash Kumar Biswal  
Company Secretary & Senior Vice President-Legal

Place: New Delhi  
Date : October 20, 2025

**FORM A  
PUBLIC ANNOUNCEMENT**  
(Under Regulation 6 of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)  
FOR THE ATTENTION OF THE CREDITORS OF ATMA RAM HOUSE INVESTMENT PRIVATE LIMITED

**RELEVANT PARTICULARS**

1 Name of corporate debtor	Atma Ram House Investment Private Limited
2 Date of incorporation of corporate debtor	14/12/1965
3 Authority under which corporate debtor is incorporated / registered	Registrar of Companies, Delhi
4 Corporate Identity No. / Limited Liability Identification No. of corporate debtor	U65921DL1965PTC004523
5 Address of the registered office and principal office (if any) of corporate debtor	Registered Office: 5 Tolstoy Marg Connaught Place, New Delhi, Delhi, India, 110001 Principal Office: Plot No 78, Industrial area phase 1, Chandigarh, Chandigarh, India, 160002
6 Insolvency commencement date in respect of corporate debtor	12/11/2025 (Order received on 15.11.2025)
7 Estimated date of closure of insolvency resolution process	11.05.2026
8 Name and registration number of the insolvency professional acting as interim resolution professional	Mr. Santanu T Ray Reg No: IBBI/IPA-002/PI-N00360/2017-2018/11055
9 Address and e-mail of the interim resolution professional, as registered with the Board	Add: 144, 14th Floor, Mittal Court, B wing, Nariman Point, Mumbai, Maharashtra-400021 Email id: <a href="mailto:santanu@aaainsolvency.com">santanu@aaainsolvency.com</a>
10 Address and e-mail to be used for correspondence with the interim resolution professional	Add: 144, 14th Floor, Mittal Court, B wing, Nariman Point, Mumbai, Maharashtra - 400021. Email id: <a href="mailto:atmaramhouseinvestment.lbc@gmail.com">atmaramhouseinvestment.lbc@gmail.com</a>
11 Last date for submission of claims	29.11.2025
12 Classes of creditors, if any, under clause (b) of section 6A of section 21, ascertained by the interim resolution professional	N.A.
13 Names of Insolvency Professionals identified to act as Authorised Representative of creditors in a class (Three names for each class)	N.A.
14 (a) Relevant Forms and (b) Details of authorized representatives available at	a) Relevant Forms available at <a href="https://ibbi.gov.in/en/home/downloads">https://ibbi.gov.in/en/home/downloads</a> b) N.A.

Notice is hereby given that the National Company Law Tribunal has ordered the commencement of a corporate insolvency resolution process of Atma Ram House Investment Private Limited on 12.11.2025. The creditors of Atma Ram House Investment Private Limited are hereby called upon to submit their claims with proof or before 29.11.2025 to the interim resolution professional at the address mentioned against entry No. 10.

The financial creditors shall submit their claims with proof by electronic means only. All other creditors may submit the claims with proof, in person, by post or by electronic means.

A financial creditor belonging to a class, as listed against the entry No. 12, shall indicate its choice of authorised representative from among the three insolvency professionals listed against entry No.13 as authorised representative of the class [specify class] in Form CA.

Submission of false or misleading proof of claim shall attract penalties.

Sd/-  
Santanu T Ray  
Interim Resolution Professional

In the matter of Atma Ram House Investment Private Limited  
AFB - IBBI/PA-002/PI-N00360/2017-2018/11055

IBBI - IBBI/PA-002/PI-N00360/2017-2018/11055

Date: 15.11.2025  
Place: Mumbai

Continued from previous page...

6 Allocation to Market Maker (After Technical Rejections):

The Basis of Allotment to Market Maker, who have bid at Offer Price of ₹114.00 per equity shares or above, was finalized in consultation with BSE. The category was subscribed by 1.00000 times i.e. for 3,09,600 shares the total number of shares allotted in this category is 3,09,600 Equity Shares to 1 successful applicant. The category wise details of the Basis of Allotment are as under:

S.No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ration of allottees to applicants	Total No. of shares allocated/allotted
ANCHOR	3,09,600	1	100.00	3,09,600				



(Please scan this QR Code to view the Prospectus)



# MAHAMAYA LIFESCIENCES LIMITED

Corporate Identification Number: U24233DL2002PLC115261

Our Company was originally incorporated as a private limited Company under the name of "Mahamaya Life Sciences Private Limited" under the provisions of the Companies Act, 1956 and certificate of incorporation was issued by the Assistant Registrar of Companies, NCT of Delhi & Haryana, on May 07, 2002. Further, our Company name was changed from "Mahamaya Life Sciences Private Limited" to "Mahamaya Lifesciences Private Limited" and a fresh certificate of incorporation dated February 15, 2016 was issued by the Registrar of Companies, Delhi. Moreover, a special resolution was passed at the Extra-Ordinary General Meeting of our Company held on October 29, 2024 for conversion of our Company into a public limited Company and the name of our Company was changed from "Mahamaya Lifesciences Private Limited" to "Mahamaya Lifesciences Limited". A fresh certificate of incorporation consequent to change of name was issued by the Registrar of Companies, Delhi on November 19, 2024. The Corporate Identity Number of our Company is U24233DL2002PLC115261.

Registered Office: Unit No: DPT – 033, Ground Floor, Plot No: 79 – 80, DLF Prime Tower, F – Block, Okhla, Phase – 1, New Delhi – 110020, India.

Corporate Office: 369, 370, 370A &amp; 370B, 3rd Floor, Tower B-1, Spaze iTech Park, Sector-49, Sohna Road, Gurugram 122018

Contact Person: Ms. Shilpi Bhardwaj, Company Secretary and Compliance Officer; Tel: +91-1146561474 E-mail: cs@mahamayalifesciences.com Website: https://www.mahamayalifesciences.com/

## PROMOTERS OF OUR COMPANY: Mr. Krishnamurthy Ganesan, Mrs. Lalitha Krishnamurthy and Mr. Prashant Krishnamurthy

## THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LTD (BSE SME)

The company specializes in the manufacturing of pesticide formulations and supply bulk formulations catering to both Indian agrochemical companies, as well as multinational corporations (MNCs). We began our journey by focusing on import and registration of vital pesticide molecules (Technical) that were not produced domestically in India. We imported these molecules after lot of product research and worked on registering them with the Central Insecticides Board and Registration Committee (CIBRC) under the Department of Agriculture, Government of India. After successful registration we marketed these molecules both as technical and as value added end use formulations for both domestic manufacturers and MNCs.

For further details, see chapter titled "Our Business" beginning on page 124 of the Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF UP TO 61,78,800\* EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF MAHAMAYA LIFESCIENCES LIMITED ("MLL" OR THE "COMPANY") FOR CASH AT PRICE OF ₹ 114/- PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF 104/- PER EQUITY SHARE) (THE "OFFER PRICE"), AGGREGATING UP TO ₹ 7,043.83 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF UP TO 56,38,800\* EQUITY SHARES AGGREGATING TO ₹ 6,428.23 LAKHS ("THE "FRESH OFFER") AND AN OFFER FOR SALE OF UP TO 5,40,000\* EQUITY SHARES (THE "OFFERED SHARES") OF FACE VALUE OF ₹ 10/- EACH AGGREGATING UP TO ₹ 615.60 LAKHS ("OFFER FOR SALE") COMPRISING OF 3,70,000\* EQUITY SHARES AGGREGATING UP TO ₹ 421.80 LAKHS BY KRISHNAMURTHY GANESAN AND 1,70,000\* EQUITY SHARES AGGREGATING UP TO ₹ 193.80 LAKHS BY LALITHA KRISHNAMURTHY (COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS") OUT OF WHICH 3,09,600 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN OFFER PRICE OF ₹ 114/- PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ 352.94 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE OFFER (THE "MARKET MAKER RESERVATION PORTION"). THE OFFER LESS MARKET MAKER RESERVATION PORTION I.E. NET OFFER OF 58,69,200\* EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN OFFER PRICE OF ₹ 114/- PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ 6,690.89 LAKHS IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND NET OFFER WILL CONSTITUTE 26.40% AND 25.08% RESPECTIVELY OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ANCHOR INVESTOR OFFER PRICE: RS. 114/- PER EQUITY SHARE.

THE FACE VALUE OF THE EQUITY SHARE IS RS.10/- EACH AND OFFER PRICE IS RS. 114/- PER EQUITY SHARE.

THE OFFER PRICE IS 11.4 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

### BID/OFFER PERIOD

ANCHOR INVESTOR BIDDING DATE WAS: MONDAY, NOVEMBER 10, 2025

BID/OFFER OPENED ON: TUESDAY, NOVEMBER 11, 2025; BID/OFFER CLOSED ON: THURSDAY, NOVEMBER 13, 2025

### RISK TO INVESTORS:

Summary description of key risk factor based on materiality:

- Our top ten customers constituted 71.35%, 76.26%, 83.14% and 71.12% of our sales for the period ended June 30, 2025 and for the financial year ended March 31, 2025, March 31, 2024, March 31, 2023 respectively. Absence of large number of customers, dependence on few customers and creating a customer concentration risk which may have an adverse impact on our business operations and financial performance.
- Our Company has not entered into long-term agreements with our customers for purchasing our products nor for the supply of raw materials with our suppliers. We are subject to uncertainties in demand/supply and there is no assurance that these customers and suppliers will continue to purchase our products or sell raw materials to us or that they will not scale down their orders. This could impact the business and financial performance of our Company.
- Raw materials constitute a significant percentage of our Company's total expenses. Any increase in prices and any decrease in the supply would materially adversely affect our Company's business.
- We are required to obtain and/or renew certain registrations from the CIB&RC for our products manufactured in India. We also register our products in overseas jurisdictions through our International Distribution Partners to enable exports to such countries. Any failure to successfully register our products in India or in the international markets may affect our results of operations and financial condition.
- We have complied with the timely filing requirement for statutory dues but have faced delays in payment due to technical issue.
- We are party to certain litigation and claims. These legal proceedings are pending at different levels of adjudication before various forums and regulatory authorities. Any adverse decision may make us liable to liabilities/penalties and may adversely affect our reputation, business, and financial status.
- Perception of non-compliance due to non-reflection of TDS payment on the TRACES Portal
- We may not be able to avail funding from banks or financial institution for our future working capital requirements. The failure to obtain such financing may adversely affect our ability to grow and our future profitability.
- The Objects of the Offer for which funds are being raised have not been appraised by any bank or financial institution. The deployment of funds is entirely at the discretion of our management and as per the details mentioned in the section titled "Objects of the Offer". Any revision in the estimates may require us to reschedule our expenditure and may have a bearing on our expected revenues and earnings.
- Our Company had negative cash flows, details of which are given below. Sustained negative cash flow could adversely impact our business, financial condition and results of operations.

For further details please refer chapter titled 'Risk Factors' beginning on page no. 31 of the Prospectus.

- The Merchant Banker associated with the Offer has handled 3 Public Issues in the past 3 financial years, out of which nil Issue closed below Issue Price on listing date.
- The average cost of acquisition of Equity Shares by the Individual Promoters is:

Name of Promoters and Selling Shareholders	Number of Equity Shares held	Average Cost of Acquisition per equity share (in Rs.)
Mr. Krishnamurthy Ganesan (Promoter and Selling Shareholder)	54,86,250	0.67
Mrs. Lalitha Krishnamurthy (Promoter and Selling Shareholder)	41,20,875	0.01
Mr. Prashant Krishnamurthy (Promoter)	41,20,875	0.00

As certified by N. Naresh &amp; Co. Chartered Accountant, Statutory Auditor by way of their certificate dated January 09, 2025

• P/E ratio based on the Basic and Diluted EPS, as restated for Financial Year 2024-25 for the Company is 15.00 at cap price

• Weighted Average Return on Net worth for Financial Year 2024-25, 2023-24 and 2022-23 is 23.36%

• The Weighted average cost of acquisition of all Equity Shares transacted in the last eighteen months, one year and three years immediately preceding the date of the Prospectus is set forth below:

Period	Weighted Average Cost of Acquisition (in Rs.)	Cap price of Price Band is 'X' times of the weighted average cost of acquisition	Range of acquisition price: Lowest Price – Highest Price (in Rs.)
Last one year	NA**	NA**	NA**
Last eighteen months	8.24	13.84	0- 201.65
Last three years	8.24	13.84	0- 201.65

\*\*NA = Not Applicable since no transaction in last one year

As certified by M/s N Naresh &amp; Co, Chartered Accountants the statutory auditors of our Company pursuant to their certificate dated November 03, 2025

• Weighted average cost of acquisition at Floor price and Cap Price in the last 18 months:

Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares)	Floor price (i.e. ₹ 108/-)	Cap Price (i.e. ₹ 114/-)
Weighted average cost of acquisition of primary / new issue	75.15	1.44	1.52
Weighted average cost of acquisition for secondary sale/ acquisition	201.65	0.54	0.57

As certified by M/s N Naresh &amp; Co, Chartered Accountants the statutory auditors of our Company pursuant to their certificate dated November 03, 2025

## PROPOSED LISTING: TUESDAY, NOVEMBER 18, 2025

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company and Selling Shareholder, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors wherein (a) one third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs; (b) two third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than ₹10 lakhs; and (c) any unsubscribed portion in either of the sub-categories specified in clauses (a) or (b), may be allocated to Applicants in the other sub-category of Non-Institutional Investors; and not less than 35.00% of the Net Offer shall be available for allocation to Individual Investors, who applies for minimum application size, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page number 316 of this Prospectus

### SUBSCRIPTION DETAILS

The Company received 8 Anchor Investor Application Forms from 8 Anchor Investors (including Nil mutual funds through Nil Mutual Fund schemes) for 2,031,600 Equity Shares. Such 8 Anchor Investors through 7 Anchor Investor Application Forms were allocated 17,52,000 Equity Shares at a price of Rs.114/- per Equity Share under the Anchor Investor Portion, aggregating to Rs. 199,728,000/- The Offer was subscribed to the extent of 1.47 times (including the Anchor Investor Portion) as per the bid books of BSE (the "Bid Files") after removing multiple and duplicate bids & Bid not bank cases. The Details of the Applications received from various categories (before technical rejection) are as under:

Detail of the Applications Received:

Sr. No.	Category	Number of Applications Received*	Number of Equity Shares applied	Number of Equity Shares reserved as per Prospectus	Number of times subscribed	Application Amount (in ₹)
1	Anchor Investors	8	20,31,600	17,52,000	1.16	23,16,02,400
2	Market Maker	1	3,09,600	3,09,600	1.00	3,52,94,400
3	Qualified Institutional Bidders (excluding Anchor Investors)	9	14,01,600	11,76,000	1.19	15,97,82,400
4	Non Institutional Investors -More than 2 Lakhs Upto 10 Lakhs	64	2,67,600	2,94,000	0.91	3,05,06,400
5	Non Institutional Investors -Above 10 Lakhs	82	29,41,200	5,88,000	5.00	33,52,96,800
6	Individual Investors	882	21,16,800	20,59,200	1.03	24,11,49,600
<b>TOTAL</b>		<b>1,046</b>	<b>90,68,400</b>	<b>61,78,800</b>	<b>1.47</b>	<b>1,03,36,32,000</b>

Final Demand

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid Prices is as under:

नई दिल्ली

An ISO 9001:2015 certified company

Mahamaya

MAHAMAYA LIFESCIENCES

LTD

2002PLC115261

Corporate Identification Number: U24233DL2002PLC115261

Initial Public Offer

Offer Price: ₹ 114/-

Offer Date: 10-Nov-2025

Offer Expiry Date: 13-Nov-2025

Offer Status: Open

Offer Type: IPO

Offer Category: SME

Offer Status: Open

Offer Type: IPO

Offer Category: SME

Offer Status: Open

Offer Type: IPO

Offer Category: SME

Offer Status: Open

